Your search history is turned on.
Date: March 1, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
BELLUS Sant participera la Cowen 43rd Annual Health Care Conference BELLUS Sant participera la Cowen 43rd Annual Health Care Conference LAVAL, Qubec--(BUSINESS WIRE)--March 1, 2023--BELLUS Sant inc. (Nasdaq : BLU; TSX : BLU) ( BELLUS Sant ou la socit ), une socit biopharmaceutique au stade clinique qui dveloppe de nouveaux produits thrap...
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference LAVAL, Quebec--(BUSINESS WIRE)--March 1, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...
Date: February 24, 2023 Jurisdictions: All jurisdictions
Microsoft Word - Notice of Meeting FR.docx Date: le 24 fvrier, 2023 1500, boul. Robert-Bourassa, 7e tage Montral (Qubec), H3A 3S8 www.computershare.com Destinataires: Toutes les autorits canadiennes en valeurs mobilires Objet: BELLUS SANT INC. Madame, Monsieur, Veuillez prendre note des informations relatives la prochaine assemble des dtenteu...
Microsoft Word - Notice of Meeting EN.docx Date: February 24, 2023 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: BELLUS HEALTH INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: ...
Date: February 8, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
BELLUS Sant fera une prsentation sur lexprience des patients et le fardeau que reprsente la toux chronique rfractaire au congrs annuel de lAmerican Academy of Allergy, Asthma & Immunology BELLUS Sant fera une prsentation sur lexprience des patients et le fardeau que reprsente la toux chronique rfractaire au congrs annuel de lAmerican Academy of Aller...
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting LAVAL, Quebec--(BUSINESS WIRE)...
Date: November 14, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
BELLUS Sant annonce ses rsultats financiers et faits saillants pour le troisime trimestre de 2022 BELLUS Sant annonce ses rsultats financiers et faits saillants pour le troisime trimestre de 2022 - Lancement du programme CALM de phase 3, les principaux rsultats des essais CALM-1 et CALM-2 tant attendus au deuxime semestre de 2024 et en 2025, respect...
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights - Initiated CALM Phase 3 program with topline data expected for CALM-1 and CALM-2 in the second half of 2024 and 2025, respectively - - Ended third quarter 2022 with US$364.4 million in cas...
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ramzi Benamar, Chief Financial Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of BELLUS Health Inc. (the issuer) for the interim period ended September 30, 2022....
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Roberto Bellini, President and Chief Executive Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of BELLUS Health Inc. (the issuer) for the interim period ended Septem...